Public notice

Activity of a Novel Anti-Inflammatory Agent F-3,6′-dithiopomalidomide as a Treatment for Traumatic Brain Injury

관리자 │ 2023-01-17

HIT

585
The therapeutic efficacy results of a novel immunomodulatory imide drug developed under the Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) have been published in the peer-reviewed publication, Biomedicines (September 30, 2022). 

The publication, titled, "Activity of a Novel Anti-Inflammatory Agent F-3,6′-dithiopomalidomide as a Treatment for Traumatic Brain Injury"



Previous Post 3,6′- and 1,6′-Dithiopomalidomide Mitigate Ischemic Stroke in Rats and Blunt...
Next Post A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerat...